Table 2 Summary of response after 3 and 6 administrations of Radium-223 in the entire cohort of patients in lesion-by-lesion analysis according to PERCIST criteria on 18F FDG PET/CT and according to SUVmax on 18FNa PET/CT

From: RADTHYR: an open-label, single-arm, prospective multicenter phase II trial of Radium-223 for the treatment of bone metastases from radioactive iodine refractory differentiated thyroid cancer

Variable Response Lytic Sclerotic Mixed Not interpretable
   18FDG PET 18FNa PET 18FDG PET 18FNa PET 18FDG PET 18FNa PET 18FDG PET 18FNa PET
3 months evaluation Number 15 17 2 1 10 10 1 1
PR 1 0 0 0 1 0 0 0
SD 8 15 1 1 8 10 1 1
PD 6 2 1 0 1 0 0 0
  Number 12 15 1 1 9 10 1 1
6 months* evaluation PR 0 2 0 0 0 2 0 0
SD 9 13 1 1 5 8 0 1
PD 3 0 0 0 4 0 1 0
  1. PERCIST PET Response Criteria In Solid Tumor
  2. *1 patient was not evaluable at 6 months and the total number of lesions is reduced from 28 to 23 lesions between 3 and 6 months at 18F-FDG PET/CT and from 29 to 27 at 18F-FNa PET/CT